<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01191723</url>
  </required_header>
  <id_info>
    <org_study_id>MAP0004-CL-P103</org_study_id>
    <nct_id>NCT01191723</nct_id>
  </id_info>
  <brief_title>QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo</brief_title>
  <official_title>A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered
      by Oral Inhalation) with Moxifloxacin and Placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes</measure>
    <time_frame>baseline and 30 minutes</time_frame>
    <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</measure>
    <time_frame>baseline and 2 hours</time_frame>
    <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTcF for MAP0004 3.0mg and Placebo at 30 Minutes</measure>
    <time_frame>baseline and 30 minutes</time_frame>
    <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in QTcF for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</measure>
    <time_frame>baseline and 2 hours</time_frame>
    <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Heart Rate for MAP0004 3.0mg, Placebo, and Moxifloxacin at 30 Minutes and 2 Hours</measure>
    <time_frame>baseline, 30 minutes, and 2 hours</time_frame>
    <description>The heart rate is a measure of how fast or slow the heart beats (measured in beats per minute). A negative change indicates a decrease in heart rate and a positive change indicates an increase in heart rate.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.
Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>There was 48 hour wash-out between treatment visits.
Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.
Tablets were orally administered after oral inhalation dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MAP0004</intervention_name>
    <description>3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaler Placebo</intervention_name>
    <description>Placebo for Inhaler administered in Treatments A and C</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400mg encapsulated tablet administered in Treatment A as per protocol</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
    <other_name>Avelox®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Capsule</intervention_name>
    <description>Placebo for Moxifloxacin administered in Treatment B and Treatment C</description>
    <arm_group_label>Treatment A, then Treatment B, then Treatment C</arm_group_label>
    <arm_group_label>Treatment A, then Treatment C, then Treatment B</arm_group_label>
    <arm_group_label>Treatment B, then Treatment A, then Treatment C</arm_group_label>
    <arm_group_label>Treatment B, then Treatment C, then Treatment A</arm_group_label>
    <arm_group_label>Treatment C, then Treatment A, then Treatment B</arm_group_label>
    <arm_group_label>Treatment C, then Treatment B, then Treatment A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able to provide a signed, executed written informed consent

          2. Healthy non-smoking adult volunteers: Male or Female subjects 18 to 45 years old

          3. Female subjects who are practicing adequate contraception (see section 4.4) or who are
             sterile

          4. No known cardiac disease

          5. Normal hemoglobin values

          6. Normal or not clinically significant 12-lead Electrocardiogram

               -  Heart rate ≥ 40 and ≤ 100 at Visit 1 vital signs assessment (resting)

               -  Subjects with QTcF interval duration &lt;430 msec for males and &lt;450 msec for
                  females obtained from the ECG recorder's measurements on the screening ECG taken
                  after at least 5 minutes of quiet rest in supine position

          7. Demonstrated ability to properly use the Tempo® Inhaler

          8. Subject has not donated blood in the last 56 days

        Exclusion Criteria:

          1. Contraindication to dihydroergotamine mesylate (DHE)

          2. History of hemiplegic or basilar migraine

          3. Family history of long QT syndrome

          4. Participation in another investigational trial during the 30 days prior to Visit 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2010</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>August 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 22, 2013</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Dihydroergotamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This is a 3-treatment, 3-period, 6-sequence crossover study. Each subject received all 3 treatments in a randomly assigned order: treatments A, B, and C, the sequences were ABC, ACB, BAC, BCA, CAB, and CBA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment A, Then B, Then C</title>
          <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4.</description>
        </group>
        <group group_id="P2">
          <title>Treatment A, Then C, Then B</title>
          <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.
Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4.</description>
        </group>
        <group group_id="P3">
          <title>Treatment B, Then A, Then C</title>
          <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
Treatment C = inhaler placebo and placebo capsules at Visit 4.</description>
        </group>
        <group group_id="P4">
          <title>Treatment B, Then C, Then A</title>
          <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.</description>
        </group>
        <group group_id="P5">
          <title>Treatment C, Then A, Then B</title>
          <description>Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.
Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4.</description>
        </group>
        <group group_id="P6">
          <title>Treatment C, Then B, Then A</title>
          <description>Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Subjects</title>
          <description>All subjects enrolled in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="6.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes</title>
        <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>baseline and 30 minutes</time_frame>
        <population>Patients with data available at required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C (Placebo)</title>
            <description>Treatment C = inhaler placebo and placebo capsules.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (MAP0004 3.0mg)</title>
            <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 Minutes</title>
          <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>Patients with data available at required time point were included in the analysis population.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.8" spread="20.1"/>
                    <measurement group_id="O2" value="409.6" spread="20.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 30 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="6.2"/>
                    <measurement group_id="O2" value="-4.6" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</title>
        <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>baseline and 2 hours</time_frame>
        <population>Patients with data available at required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C (Placebo)</title>
            <description>Treatment C = inhaler placebo and placebo capsules at Visit 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (MAP0004 3.0mg)</title>
            <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A (Moxifloxacin)</title>
            <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</title>
          <description>The corrected QT interval, individualized (QTcI) is a measurement of the electrical impulses through the largest part of the heart muscle individualized for subject pre-dose values. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>Patients with data available at required time point were included in the analysis population.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="408.8" spread="20.1"/>
                    <measurement group_id="O2" value="409.6" spread="20.9"/>
                    <measurement group_id="O3" value="408.6" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="7.0"/>
                    <measurement group_id="O2" value="-5.1" spread="6.7"/>
                    <measurement group_id="O3" value="9.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTcF for MAP0004 3.0mg and Placebo at 30 Minutes</title>
        <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>baseline and 30 minutes</time_frame>
        <population>Patients with data available at required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C (Placebo)</title>
            <description>Treatment C = inhaler placebo and placebo capsules.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (MAP0004 3.0mg)</title>
            <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF for MAP0004 3.0mg and Placebo at 30 Minutes</title>
          <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>Patients with data available at required time point were included in the analysis population.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.8" spread="18.4"/>
                    <measurement group_id="O2" value="407.7" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 30 mins</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="6.4"/>
                    <measurement group_id="O2" value="-4.7" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in QTcF for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</title>
        <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
        <time_frame>baseline and 2 hours</time_frame>
        <population>Patients with data available at required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C (Placebo)</title>
            <description>Treatment C = inhaler placebo and placebo capsules at Visit 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (MAP0004 3.0mg)</title>
            <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A (Moxifloxacin)</title>
            <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in QTcF for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 Hours</title>
          <description>The Fridericia corrected QT interval(QTcF) is a measurement of the electrical impulses through the largest part of the heart muscle. A negative change is a shortening of the QTc interval, a positive change is a lengthening of the QTc interval.</description>
          <population>Patients with data available at required time point were included in the analysis population.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406.8" spread="18.4"/>
                    <measurement group_id="O2" value="407.7" spread="20.0"/>
                    <measurement group_id="O3" value="407.0" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="6.9"/>
                    <measurement group_id="O2" value="-3.9" spread="6.0"/>
                    <measurement group_id="O3" value="8.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Heart Rate for MAP0004 3.0mg, Placebo, and Moxifloxacin at 30 Minutes and 2 Hours</title>
        <description>The heart rate is a measure of how fast or slow the heart beats (measured in beats per minute). A negative change indicates a decrease in heart rate and a positive change indicates an increase in heart rate.</description>
        <time_frame>baseline, 30 minutes, and 2 hours</time_frame>
        <population>Patients with data available at required time point were included in the analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment C (Placebo)</title>
            <description>Treatment C = inhaler placebo and placebo capsules at Visit 3.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B (MAP0004 3.0mg)</title>
            <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules.</description>
          </group>
          <group group_id="O3">
            <title>Treatment A (Moxifloxacin)</title>
            <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate for MAP0004 3.0mg, Placebo, and Moxifloxacin at 30 Minutes and 2 Hours</title>
          <description>The heart rate is a measure of how fast or slow the heart beats (measured in beats per minute). A negative change indicates a decrease in heart rate and a positive change indicates an increase in heart rate.</description>
          <population>Patients with data available at required time point were included in the analysis population.</population>
          <units>beats per minute (bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" spread="9.1"/>
                    <measurement group_id="O2" value="64.6" spread="9.5"/>
                    <measurement group_id="O3" value="63.8" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 30 minutes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="4.2"/>
                    <measurement group_id="O2" value="-0.2" spread="5.8"/>
                    <measurement group_id="O3" value="2.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline at 2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="4.3"/>
                    <measurement group_id="O2" value="-4.4" spread="6.7"/>
                    <measurement group_id="O3" value="0.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events are presented by treatment arm, not by individual treatment (intervention) received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment C (Placebo)</title>
          <description>Treatment C = inhaler placebo and placebo capsules</description>
        </group>
        <group group_id="E2">
          <title>Treatment B (MAP0004 3.0mg)</title>
          <description>Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules</description>
        </group>
        <group group_id="E3">
          <title>Treatment A (Moxifloxacin)</title>
          <description>Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP, Scientific Affairs</name_or_title>
      <organization>MAP Pharmaceuticals Inc., a wholly owned subsidiary of Allergan</organization>
      <phone>650-386-3100</phone>
      <email>dkellerman@mappharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

